There were 1,362 press releases posted in the last 24 hours and 397,165 in the last 365 days.

Immunomodulators Market is Expected to Grow at a CAGR of 5.15% from 2021 to 2028

The global immunomodulators market is projected to reach USD 255.67 billion by 2028, at a CAGR of 5.15% from 2021 to 2028.

NEWARK, UNITED STATES, NEW JERSEY, October 28, 2021 /EINPresswire.com/ -- As per the report published by The Brainy Insights, the global immunomodulators market is expected to grow from USD 171.05 billion in 2020 to USD 255.67 billion by 2028, at a CAGR of 5.15% during the forecast period 2021-2028. The North America region emerged as the largest market for the immunomodulators market and valued at USD 66.19 billion in 2020. This is because North America has the highest number of populations suffering from autoimmune diseases. On the other hand, the Asia Pacific region is anticipated to hold a considerable market share in the global immunomodulators market, owing to favourable government regulations and increasing healthcare expenditure in countries such as India and China.

Get Free Sample Report: https://www.thebrainyinsights.com/enquiry/sample-request/12509

Some of the major companies in the global immunomodulators market are Hoffmann-La Roche Ltd., Amgen Inc., Abbott Laboratories, Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Eli Lilly and Company, Pfizer Inc., Biogen Inc., Teva Pharmaceuticals, Pandion Therapeutics, Inc., and aTyr Pharma, Inc. among others. The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global immunomodulators industry. For instance, in January 2020, KYORIN Holdings, Inc. today announced that its wholly-owned subsidiary KYORIN Pharmaceutical Co., Ltd has entered into a collaboration and license agreement with aTyr Pharma, Inc. for Japan with regard to ATYR1923, aTyr’s novel immunomodulator to develop and commercialize ATYR1923 for interstitial lung diseases in Japan.

The type segment is divided into immunosuppressants and immunostimulants. The immunosuppressants segment further classified into calcineurin inhibitors, antimetabolites, glucocorticoids, and others. Immunostimulants further divided into vaccines, antibodies, others. Immunosuppressants segment led the immunomodulators market with the highest market share and valued at USD 91.08 billion in 2020. The route of administration segment includes oral, injectable, and intravenous. The oral route of administration is estimated to grow at the highest CAGR of 5.9% over the forecast period, as it is one of the most convenient and usually the safest and least expensive route of administration.

The application segment includes respiratory, human immunodeficiency virus (HIV), oncology, and others. Other segment includes disease such as multiple sclerosis, Crohn's disease, and rheumatoid arthritis. Others segment accounted for the major market share of 45.6% in 2020. This is mainly due to the widely used of immunomodulators for the treatment of these diseases.

Get Full Access to Report: https://www.thebrainyinsights.com/report/immunomodulators-market-12509

Global immunomodulators market is witnessing a considerable growth owing to increasing incidences of autoimmune diseases across the globe. Immunomodulator is an effective treatment for people with autoimmune disease such as Crohn's disease and multiple sclerosis (MS). However, adverse effects of immunomodulators such as infection, both primary infection and reactivation of latent infections, hindering the market, over the forecast period.

Customization of the Report:
The customization of this report is available as per the client’s need. The report can be customized according to your requirements. We consistently update our research offerings to provide our clients with the latest trends in the market. For customization and to know more about this business report, please contact our sales team at sales@thebrainyinsights.com or +1-315-215-1633. Our sales executives will ensure that you can get a report that fulfills your requirements and suits your needs.

About Us
The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Mark Stone
The Brainy Insights
+1 315-215-1633
email us here